BIOA

Analyst Sentiment

Wall St. Consensus
Buy
3 analysts·Low coverage
67
Score
2 Buy (67%)1 Hold (33%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
267%
Hold
133%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$23.00
+30.2%
Consensus
$45.00
+154.8%
Bull
$62.00
+251.1%
12-Month Target Range3 analysts
$23.00$45.00$62.00
Current $17.66Consensus
Current Price
$17.66
Upside to Consensus
$27.34

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+207.13%
EPS
FY2028
Rev-80.94%
EPS
FY2029
Rev+461.03%
EPS

Earnings Surprises

Recent Analyst Actions

May 13, 2026BTIG
BioAge Labs initiated with a Buy at BTIG
Target:$40.00
+119.9%from $18.19
Mar 27, 2026Needham
BioAge Labs initiated with a Buy at Needham
Target:$50.00
+209.6%from $16.15
Feb 18, 2026Jefferies
BioAge Labs upgraded to Buy from Hold at Jefferies
Target:$62.00
+215.8%from $19.63
Feb 4, 2026Morgan Stanley
BioAge Labs price target raised to $23 from $12 at Morgan Stanley
Target:$23.00
+15.1%from $19.98
Dec 5, 2025Morgan Stanley
BioAge Labs upgraded to Equal Weight from Underweight at Morgan Stanley
Target:$12.00
+5.3%from $11.40
Mar 7, 2025Morgan Stanley
BioAge Labs assumed with an Underweight at Morgan Stanley
Target:$5.00
+9.9%from $4.55
Dec 9, 2024Jefferies
Jefferies Downgrades BioAge Labs Inc (BIOA) to Hold
Target:$7.00
+50.5%from $4.65
Oct 21, 2024Citigroup
BioAge Labs initiated with a Buy at Citi
Target:$45.00
+88.6%from $23.86
Oct 21, 2024Jefferies
Jefferies Starts BioAge Labs Inc (BIOA) at Buy
Target:$42.00
+76.0%from $23.86
Oct 21, 2024Morgan Stanley
Morgan Stanley Starts BioAge Labs Inc (BIOA) at Overweight
Target:$40.00
+67.6%from $23.86